After years of being a rumored biotech buyout target, Mirati was ultimately acquired by Bristol Myers Squibb earlier this month for $4.8 billion. But the pharma buyer once offered more than double that price, a securities filing reveals.
Through the Oct. 8 deal, Bristol Myers is entering a rivalry with…
Click here to view original post
